Methylation of serum gene is an independent prognostic marker in colorectal cancer.

There is an increasing demand for accurate prognostication for colorectal cancer (CRC). This study sought to assess prognostic potentials of methylation targets in the serum of CRC patients. A total of 165 CRC patients were enrolled in this prospective study. Promoter methylation levels of seven genes in pre-operative sera and matched tumor tissues were evaluated by quantitative methylation-specific PCR. Kaplan-Meier test, and univariate and multivariate Cox proportional hazards regression models were used for survival analyses. After a median follow-up of 56 months, 43 patients (28.7%) experienced tumor recurrence. In univariate survival analyses, serum methylation levels of and L were significantly predictive of cancer-specific death (<0.005 for both). The former was also a significant predictor for tumor recurrence (=0.007). Independent prognostic effects of serum methylation levels of were revealed by multivariate Cox regression model (=0.031 and =0.003 for cancer death and recurrence, respectively). When focusing on stage II and III patients, prognostication with serum methylated remained significant. Methylated detected in all serum samples can be traced back to the matched primary tumor tissues. We believe that methylated detected in the pre-operative sera of CRC patients appear to be a novel promising prognostic marker and probably can be auxiliary to tumor staging system and serum carcinoembryonic antigen towards better risk stratification.